Illustration: Axios Visuals
SanegeneBio has landed a licensing collaboration with Genentech worth up to $1.5 billion to develop an RNAi medicine, the companies announced Monday.
The big picture: Genentech has been an active partner for biotech companies, inking agreements with Caris Life Sciences and Repertoire Immune Medicines in the last year.
